GlassScriptPhysician profile
Joseph Onorato
NPI 1992882773
$5,423.73
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $284 · 2021: $279 · 2022: $995 · 2023: $1,163 · 2024: $750 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,628.64 | 2019-2023 | |
| Pfizer INC. | $890.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $810.50 | 2019-2025 | |
| Abbvie INC. | $349.28 | 2020-2025 | |
| Genzyme Corporation | $242.26 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $158.34 | 2019-2023 | Dupixent |
| Galderma Laboratories, L.P. | $157.50 | 2019-2024 | Dysport, Oracea, Epsolay |
| Lilly USA, LLC | $149.52 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $144.17 | 2024 | Daxxify |
| Leo Pharma INC. | $132.19 | 2021-2025 | Anzupgo |
| Amgen INC. | $107.38 | 2022-2024 | Otezla |
| Allergan, INC. | $104.34 | 2019-2022 | |
| Incyte Corporation | $97.54 | 2021-2024 | Opzelura |
| Journey Medical Corporation | $90.42 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $86.35 | 2020-2023 | Winlevi, Absorica Ld |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $57.40 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.50 | 2022-2023 | Spevigo |
| Blueprint Medicines Corporation | $47.27 | 2022 | |
| Mission Pharmacal Company | $30.80 | 2021-2022 | |
| Organogenesis INC. | $22.35 | 2024 | |
| Verrica Pharmaceuticals INC. | $18.99 | 2025 | Ycanth |
| Prugen, INC. Pharmaceuticals | $16.82 | 2019 | |
| Aclaris Therapeutics, INC. | $14.31 | 2019 | |
| Almirall LLC | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Onorato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.